Shalby Ltd Q3 FY25 Results

The company has shown a decent consolidated performance in Q3’FY25 with a revenue of 281 crores with growth of 27.4% on y-o-y basis. The major growth has been contributed from our implant business and acquisition of Delhi NCR hospital in current calendar year. I'm pleased to announce that our hospital segment has maintained consistent performance across key operational metrics, witnessing a 7.9% rise in In-patient count (including day care) year-on-year in Q3 FY 25. Notably, ARPOB and ALOS stood at Rs.42,704 and 3.62 respectively in Q3 FY 25, compared to Rs. 37,342 and 3.79 in the corresponding quarter of the previous yearimproved by 14.4% and 4.5% respectively.

During the third quarter of this financial year, our implant business made significant progress, generating revenues of INR 269 million up by 25% Y OY, with contributions from the USA and OUS at 33% and 67% respectively. We are actively focused on bolstering our team with skilled professionals, transitioning our sales mix to retail customers from wholesale, enhancing operational capacity and efficiency, expanding our product pipeline through extensive research and development efforts, and significantly reducing procurement costs. The reception of our Shalby Advanced Technology implants in hospitals across all markets that we have launched has been highly positive, and we have received additional orders from the South Asian market. Our strategic clinical trial agreement with Monogram Technology will also benefit SAT Inc. in expanding and growing internationally in other countries.